Austin Health

Title
Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel modulating antiseizure medications.
Publication Date
2023-01-17
Author(s)
Nightscales, Russell
Barnard, Sarah
Laze, Juliana
Chen, Zhibin
Tao, Gerard
Auvrez, Clarissa
Sivathamboo, Shobi
Cook, Mark J
Kwan, Patrick
Friedman, Daniel
Berkovic, Samuel F
D'Souza, Wendyl
Perucca, Piero
Devinsky, Orrin
O'Brien, Terence J
Type of document
Journal Article
OrcId
0000-0001-9108-207X
0000-0003-0517-2533
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-1888-6917
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0001-7310-276X
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0003-4580-841X
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-7855-7066
0000-0003-0044-4632
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1002/epi4.12693
Abstract
In vitro data prompted U.S Food and Drug Administration warnings that lamotrigine, a common sodium channel modulating anti-seizure medication (NaM-ASM), could increase risk of sudden death in patients with structural or ischaemic cardiac disease, however its implications for Sudden Unexpected Death in Epilepsy (SUDEP) are unclear.
Link
link
Citation
Epilepsia open 2023; 8(2)
Jornal Title
Epilepsia Open
ISSN
2470-9239

Files:

NameSizeformatDescriptionLink